(Q44237462)

1 December 2017

title

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response (English)

1 reference

1 December 2017

1 reference

3

1 reference

1 December 2017

David N Taylor

1

1 reference

1 December 2017

John J Treanor

2

1 reference

1 December 2017

Casey Johnson

4

1 reference

1 December 2017

Scott Umlauf

5

1 reference

1 December 2017

Langzhou Song

6

1 reference

1 December 2017

Uma Kavita

7

1 reference

1 December 2017

Ge Liu

8

1 reference

1 December 2017

Lynda Tussey

9

1 reference

1 December 2017

Karen Ozer

10

1 reference

1 December 2017

Thomas Hofstaetter

11

1 reference

1 December 2017

Alan Shaw

12

1 reference

1 December 2017

language of work or name

English

0 references

publication date

11 July 2012

1 reference

1 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

1 December 2017

volume

30

1 reference

1 December 2017

issue

39

1 reference

1 December 2017

page(s)

5761-5769

1 reference

Influenza vaccines for the future

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Evasion of Toll-like receptor 5 by flagellated bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Inflammatory Bowel Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

Bacterial flagellin is a dominant antigen in Crohn disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.086

10.1016/J.VACCINE.2012.06.086

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference